close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Post-MI Statin Use Halves Mortality Risk

Administration of statins within 24 hours after heart attack reduces in-hospital death risk more than 50%, according to a large, multi-centre study.

Researchers at UCLA and other medical centers reviewed hospital records of over 170,000 patients with acute myocardial infarction (MI). Their results are published in the 1 September issue of The American Journal of Cardiology and reported in MedPage Today on 30 August 2005.

Data analysis showed that patients who used statins shortly after hospitalization for MI had a lower mortality risk, as well as a lower rate of associated complications (excluding recurrent heart attacks).

“This analysis provides the strongest clinical evidence to date to support the hypothesis of early, direct cardioprotective effects of statins in AMI,” wrote lead author Gregg C. Fonarow, MD, and colleagues. “However, adequately powered prospective randomized clinical trials are needed to confirm these findings before it can be concluded that there are direct cardioprotective effects of statins in AMI.”

Study Protocol

The study examined whether statin use benefits hospital outcomes of patients who experienced acute MI.

Researchers retrospectively examined data from the National Myocardial Infarction Registry 4 database *, which contains information about patients who experienced acute MI at 1,230 United States hospitals.

The data examined included medical records from:

  • 17,118 patients who took statins before hospitalization for acute MI
  • 21,978 patients who took statins within 24 hours of arriving at the hospital
  • 126,128 patients who did not take statins
  • 9,411 patients who had discontinued statin therapy.
Conclusions

Researchers found that a lower mortality risk was associated with statin use within the first 24 hours.

"New or continued treatment with a statin in the first 24 hours was associated with a decreased risk of mortality compared with no statin use (4.0% and 5.3% compared with 15.4% no statin)," the authors wrote.

Also, patients who had discontinued their statin use treatment had a marginally higher mortality risk, compared with patients who took no statins (16.5% versus 15.4%).

Lower associated medical risks were also associated with early statin use and included lower risk of cardiogenic shock, ventricular tachycardia and fibrillation, rupture and cardiac arrest, but not recurrence of MI.

"We were surprised that early statin therapy showed such a striking effect immediately after a heart attack," said Dr. Fonarow, director of the Ahmanson-UCLA Cardiomyopathy Center, according to MedPage Today. "We also found that statins provided additional protection from other heart attack complications as well."

*The National Myocardial Infarction Registry 4 or “NRMI 4” database is funded by Genentech, Inc., who manufactures Activase, a thrombolytic agent.

Sources:

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohns disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...